Literature DB >> 6608520

Inhibition of mammalian xanthine oxidase by folate compounds and amethopterin.

A S Lewis, L Murphy, C McCalla, M Fleary, S Purcell.   

Abstract

We have examined the effects of folate compounds and the folate analog amethopterin (methotrexate) as inhibitors of mammalian xanthine oxidase and have found that they offer potent inhibition of the enzyme. We have compared the inhibitory potency of folic acid and its coenzyme derivative tetrahydrofolic acid to that of allopurinol, a known inhibitor of xanthine oxidase, and have demonstrated that folic acid and tetrahydrofolic acid are severalfold more potent than allopurinol as inhibitors of xanthine oxidase. Comparative inhibition constants calculated were 5.0 X 10(-7) M for folic acid. 1.25 X 10(-6) M for tetrahydrofolic acid, and 4.88 X 10(-6) M for allopurinol. Incubation of xanthine oxidase with folic acid at a concentration of 10(-6) M abolished 94% of the enzymic activity within 1 min of incubation with the enzyme. At the same concentration, allopurinol was almost ineffective as an inhibitor of xanthine oxidase. The substrate xanthine protected the enzyme against total inhibition by folic acid. Reversibility of the enzymic inhibition by folic acid was demonstrated. Folic acid-inactivated enzyme was totally regenerated either by filtration through Sephadex G-200 or by precipitation with ammonium sulfate. 2-Amino-4-hydroxypteridine was a poor substrate for the enzyme but a potent inhibitor for the oxidation of xanthine by the enzyme. The inhibition constant calculated was 1.50 X 10(-6) M. In the presence of an excess of xanthine oxidase, neither folic acid nor tetrahydrofolic acid and allopurinol exhibited any change in intensity of their absorbance or in the wavelength of their maximal absorbance that might have been suggestive of substrate utility. The folate analog amethopterin was also determined a potent inhibitor of mammalian xanthine oxidase. The inhibition constant calculated was 3.0 X 10(-5) M.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6608520

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  The clinical pharmacology of 6-mercaptopurine.

Authors:  L Lennard
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Dietary folate protects against the development of macroscopic colonic neoplasia in a dose responsive manner in rats.

Authors:  Y I Kim; R N Salomon; F Graeme-Cook; S W Choi; D E Smith; G E Dallal; J B Mason
Journal:  Gut       Date:  1996-11       Impact factor: 23.059

3.  Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment.

Authors:  Gianluigi Zaza; Meyling Cheok; Wenjian Yang; John C Panetta; Ching-Hon Pui; Mary V Relling; William E Evans
Journal:  Blood       Date:  2005-05-19       Impact factor: 22.113

4.  Role of reactive oxygen metabolites in experimental colitis.

Authors:  A Keshavarzian; G Morgan; S Sedghi; J H Gordon; M Doria
Journal:  Gut       Date:  1990-07       Impact factor: 23.059

5.  Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine.

Authors:  Ahmed F Hawwa; Jeff S Millership; Paul S Collier; Koen Vandenbroeck; Anthony McCarthy; Sid Dempsey; Carole Cairns; John Collins; Colin Rodgers; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

6.  Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate.

Authors:  F Innocenti; R Danesi; A Di Paolo; B Loru; C Favre; M Nardi; G Bocci; D Nardini; P Macchia; M Del Tacca
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

7.  Association and mediation analyses among multiple metals exposure, plasma folate, and community-based impaired estimated glomerular filtration rate in central Taiwan.

Authors:  Mu-Chi Chung; Hui-Tsung Hsu; Yan-Chiao Mao; Chin-Ching Wu; Chih-Te Ho; Chiu-Shong Liu; Chi-Jung Chung
Journal:  Environ Health       Date:  2022-04-23       Impact factor: 7.123

8.  Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-03-21       Impact factor: 2.745

9.  Association of NUDT15*3 and FPGS 2572C>T Variants with the Risk of Early Hematologic Toxicity During 6-MP and Low-Dose Methotrexate-Based Maintenance Therapy in Indian Patients with Acute Lymphoblastic Leukemia.

Authors:  Sunitha Kodidela; Patchava Dorababu; Dimpal N Thakkar; Biswajit Dubashi; Rajan Sundaram; Niveditha Muralidharan; Ravi Prasad Nidanapu; Anil Aribandi; Suresh Chandra Pradhan; Chakradhara Rao Satyanarayana Uppugunduri
Journal:  Genes (Basel)       Date:  2020-05-28       Impact factor: 4.096

10.  Folate, Vitamin B6 and Vitamin B12 Intake in Relation to Hyperuricemia.

Authors:  Yiying Zhang; Hongbin Qiu
Journal:  J Clin Med       Date:  2018-08-11       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.